Clinical trial

EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

NCT05150236

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-04-29

PhasePHASE2

Study timeline

Study start (actual)2022-04-29Date precision: day

Registry last updated2023-12-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostatic Neoplasmsunresolved

Genital Neoplasms, Maleunresolved

Urogenital Neoplasmsunresolved

Prostate Cancerunresolved

Neoplasms by Siteunresolved

Neoplasmsunresolved

Prostatic Diseaseunresolved

Interventions

177Lu-PSMA-617DRUG

IpilimumabDRUG · verified · RxNorm: ipilimumab

NivolumabDRUG · verified · RxNorm: nivolumab

Sponsors & collaborators

Australian and New Zealand Urogenital and Prostate Cancer Trials Grouplead sponsor

Prostate Cancer Foundation of Australiacollaborator

Bristol-Myers Squibbcollaborator

Advanced Accelerator Applicationscollaborator

University of Sydneycollaborator

Mapped research locations

MelbourneVictoria, Australia2 AdelaideSouth Australia, Australia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05150236 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.